SCHEMBL23263315

SCHEMBL23263315

O=c1c(-c2cncc(F)c2)cccc(Br)c1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 2/20 0.40
▸ CYP17A1 P05093 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP11B1 P15538 1/20 0.40
▸ PARP10 Q53GL7 1/20 0.40
▸ PARP11 Q9NR21 1/20 0.40
▸ GRIN1 Q05586 3/20 0.38
▸ GRIN2B Q13224 3/20 0.38
▸ HDAC4 P56524 4/20 0.37
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA7 P43166 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ CHRNB4 P30926 1/20 0.36
▸ CHRNA3 P32297 1/20 0.36
▸ HSD17B1 P14061 1/20 0.35
▸ HSD17B2 P37059 1/20 0.35
▸ KDM4C Q9H3R0 1/20 0.33
▸ CLK1 P49759 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29890214 0.84 PARP10 (0.43) CYP11B2CYP17A1CYP3A4CYP11B1PARP10
SCHEMBL23249855 0.84 PARP10 (0.43) CYP11B2CYP17A1CYP3A4CYP11B1PARP10
SCHEMBL29890449 0.80 CYP3A4 (0.41) CYP11B2CYP17A1CYP3A4CYP11B1PARP10
SCHEMBL23249843 0.80 CYP3A4 (0.41) CYP11B2CYP17A1CYP3A4CYP11B1PARP10
SCHEMBL23249822 0.79 CYP11B2 (0.43) CYP11B2CYP17A1CYP3A4CYP11B1PARP10
SCHEMBL29890460 0.79 CYP11B2 (0.43) CYP11B2CYP17A1CYP3A4CYP11B1PARP10
SCHEMBL23263139 0.76 HDAC4 (0.53) CYP11B2CYP17A1CYP3A4CYP11B1PARP10
SCHEMBL23263317 0.74 CTPS1 (0.33) CYP11B2CYP17A1CYP3A4CYP11B1PARP10
SCHEMBL23249804 0.70 PARP10 (0.43) CYP11B2CYP17A1CYP3A4CYP11B1PARP10
SCHEMBL29890183 0.70 PARP10 (0.43) CYP11B2CYP17A1CYP3A4CYP11B1PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS KINESID THERAPEUTICS, INC. (US) 2024-01-18 — — US disclosed
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS KINESID THERAPEUTICS, INC. (US) 2024-01-18 — — US disclosed
WO-2021076945-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2021-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS TXNRD2, TXNRD1, SDHB CYP11B2 5/4885CYP17A1 144/4885CYP3A4 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback